Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) Net Income towards Common Stockholders (2016 - 2026)

Ekso Bionics Holdings has reported Net Income towards Common Stockholders over the past 14 years, most recently at -$4.7 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 36.65% to -$4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.6 million, a 20.35% decrease, with the full-year FY2025 number at -$13.6 million, down 20.34% from a year prior.
  • Net Income towards Common Stockholders reached -$4.7 million in Q4 2025 per EKSO's latest filing, down from -$1.4 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$1.4 million in Q3 2025, with the low at -$4.7 million in Q4 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$3.4 million (2024), against an average of -$3.5 million.
  • Peak YoY movement for Net Income towards Common Stockholders: skyrocketed 42.88% in 2024, then plummeted 67.22% in 2025.
  • Tracing EKSO's Net Income towards Common Stockholders over 5 years: stood at -$4.6 million in 2021, then grew by 1.87% to -$4.5 million in 2022, then rose by 28.61% to -$3.2 million in 2023, then decreased by 6.19% to -$3.4 million in 2024, then crashed by 36.65% to -$4.7 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$4.7 million, -$1.4 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.